What the new hepatitis C protease inhibitors Incivek and Victrelis mean for people coinfected with HIV & HCV and for health departments. Presented at the NASTAD annual meeting 5/23/11.
Other SEP Activities - 17th Texas HIV/STD ConferenceDan Bigg
Implications of Lifting the Federal Funding Ban on Syringe Exchange at Texas HIV/STD Conference. Powerpoint by Dan Bigg, Chicago Recovery Alliance. Please use with credit to Chicago Recovery Alliance. Dan @ cra@attglobal.net or anypositivechange.org
Presentation by Daniel Raymond, the Harm Reduction Coalition's Policy Director, to the Institute of Medicine's Committee on Prevention and Control of Viral Hepatitis Infections on March 3, 2009.
A teaching aid on addressing hesitancy to Covid-19 vaccination. WHO has identified vaccine hesitancy as a major threat to global health. Learn more about how to work with patients, the public and communities to improve confidence in Covid-19 vaccines.
Hepatitis B & C - the Basics for Primary CareJarrod Lee
This presentation covers the basics in Hepatitis B & C, and is aimed at primary care physicians who may encounter such patients. It focuses mainly on the natural history, how to diagnose and monitor the disease, and when to refer to a specialist.
Best Practices in the Management of HCV/HIV Coinfection: Optimizing Treatment...Hivlife Info
Jürgen K. Rockstroh, MD, provides an update on the importance of HCV screening and the latest emerging treatment options for patients with HCV/HIV coinfection.
Other SEP Activities - 17th Texas HIV/STD ConferenceDan Bigg
Implications of Lifting the Federal Funding Ban on Syringe Exchange at Texas HIV/STD Conference. Powerpoint by Dan Bigg, Chicago Recovery Alliance. Please use with credit to Chicago Recovery Alliance. Dan @ cra@attglobal.net or anypositivechange.org
Presentation by Daniel Raymond, the Harm Reduction Coalition's Policy Director, to the Institute of Medicine's Committee on Prevention and Control of Viral Hepatitis Infections on March 3, 2009.
A teaching aid on addressing hesitancy to Covid-19 vaccination. WHO has identified vaccine hesitancy as a major threat to global health. Learn more about how to work with patients, the public and communities to improve confidence in Covid-19 vaccines.
Hepatitis B & C - the Basics for Primary CareJarrod Lee
This presentation covers the basics in Hepatitis B & C, and is aimed at primary care physicians who may encounter such patients. It focuses mainly on the natural history, how to diagnose and monitor the disease, and when to refer to a specialist.
Best Practices in the Management of HCV/HIV Coinfection: Optimizing Treatment...Hivlife Info
Jürgen K. Rockstroh, MD, provides an update on the importance of HCV screening and the latest emerging treatment options for patients with HCV/HIV coinfection.
lecture submitted to healthcare workers ( physicians,dentists,nurses,lab.technicians) to explain the best methods to avoid transmission of hepatitis through health practices
Dr. Lauri Hicks - Out-Patient Antibiotic Resistance (AMR) IssuesJohn Blue
Out-Patient Antibiotic Resistance (AMR) Issues - Dr. Lauri Hicks, Commander, U.S. Public Health Service, Medical Epidemiologist, Respiratory Diseases Branch; Medical Director, Get smart: Know When Antibiotic Work Program; Centers for Disease Control and Prevention (CDC), from the 2015 NIAA Antibiotic Symposium - Stewardship: From Metrics to Management, November 3-5, 2015, Atlanta, Georgia, USA.
More presentations at http://swinecast.com/2015-niaa-symposium-antibiotics-stewardship-from-metrics-to-management
Potential advantages of booster containing PCV regimen - Professor Shabir MadhiWAidid
This slideset, realized by Professor Shabir Madhi on the occasion of the 11th ISPPD held in Melbourne last April, evaluates the potential advantages of booster containing PCV dosing schedule.
To learn more, visit www.waidid.org!
Dr. James Hughes - Combating Antimicrobial Resistance: The Way ForwardJohn Blue
Combating Antimicrobial Resistance: The Way Forward - Dr. James Hughes, Professor of Medicine and Public Health with Joint Appointments in the School of Medicine and the Rollins School of Public Health at Emory University, from the 2014 NIAA Symposium on Antibiotics Use and Resistance: Moving Forward Through Shared Stewardship, November 12-14, 2014, Atlanta, Georgia, USA.
More presentations at http://www.swinecast.com/2014-niaa-antibiotics-moving-forward-through-shared-stewardship
Gabriel Wagner, MD
Assistant Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
COVID 19 Team-Based Approaches to Patient PopulationsCHC Connecticut
As presented as part of The Path Forward on Jan 28, 2021:
Stable housing and health outcomes are inextricably linked. When a patient loses housing – or is in jeopardy of losing housing– health outcomes suffer. COVID has led us to a moment of crisis. Thirty million to 40 million people in the United States face eviction. People of color are disproportionately impacted. Addressing housing as a social determinant of health is critical to achieving health equity. This webinar brings together experts from housing, healthcare and the intersection of both to share innovative short- and long-term solutions you can implement in your community.
Gabriel Wagner, MD
Associate Clinical Professor
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Trichomoniasis in Pregnancy - Clinical Education for ProvidersReproductiveHealth
This case-based curriculum is the product of an expert consensus meeting convened to identify practice gaps in STI management and offers guidance beyond the CDC’s STD treatment guidelines. This presentation highlights the case of Carly, a 28-year-old woman, G3 P1102, who is 30 weeks pregnant. She presents at her routine prenatal visit reporting malodorous discharge and mild vaginal irritation. Review this case to get the latest expert guidance on best practices in trichomoniasis screening and treatment.
For more evidence-based, peer reviewed slides on reproductive health topics, visit www.arhp.org/CORE. Review a free, on-demand webinar on managing prevalent & problematic STIs and earn CME at www.arhp.org/STIwebinar.
lecture submitted to healthcare workers ( physicians,dentists,nurses,lab.technicians) to explain the best methods to avoid transmission of hepatitis through health practices
Dr. Lauri Hicks - Out-Patient Antibiotic Resistance (AMR) IssuesJohn Blue
Out-Patient Antibiotic Resistance (AMR) Issues - Dr. Lauri Hicks, Commander, U.S. Public Health Service, Medical Epidemiologist, Respiratory Diseases Branch; Medical Director, Get smart: Know When Antibiotic Work Program; Centers for Disease Control and Prevention (CDC), from the 2015 NIAA Antibiotic Symposium - Stewardship: From Metrics to Management, November 3-5, 2015, Atlanta, Georgia, USA.
More presentations at http://swinecast.com/2015-niaa-symposium-antibiotics-stewardship-from-metrics-to-management
Potential advantages of booster containing PCV regimen - Professor Shabir MadhiWAidid
This slideset, realized by Professor Shabir Madhi on the occasion of the 11th ISPPD held in Melbourne last April, evaluates the potential advantages of booster containing PCV dosing schedule.
To learn more, visit www.waidid.org!
Dr. James Hughes - Combating Antimicrobial Resistance: The Way ForwardJohn Blue
Combating Antimicrobial Resistance: The Way Forward - Dr. James Hughes, Professor of Medicine and Public Health with Joint Appointments in the School of Medicine and the Rollins School of Public Health at Emory University, from the 2014 NIAA Symposium on Antibiotics Use and Resistance: Moving Forward Through Shared Stewardship, November 12-14, 2014, Atlanta, Georgia, USA.
More presentations at http://www.swinecast.com/2014-niaa-antibiotics-moving-forward-through-shared-stewardship
Gabriel Wagner, MD
Assistant Professor of Medicine
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
COVID 19 Team-Based Approaches to Patient PopulationsCHC Connecticut
As presented as part of The Path Forward on Jan 28, 2021:
Stable housing and health outcomes are inextricably linked. When a patient loses housing – or is in jeopardy of losing housing– health outcomes suffer. COVID has led us to a moment of crisis. Thirty million to 40 million people in the United States face eviction. People of color are disproportionately impacted. Addressing housing as a social determinant of health is critical to achieving health equity. This webinar brings together experts from housing, healthcare and the intersection of both to share innovative short- and long-term solutions you can implement in your community.
Gabriel Wagner, MD
Associate Clinical Professor
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Trichomoniasis in Pregnancy - Clinical Education for ProvidersReproductiveHealth
This case-based curriculum is the product of an expert consensus meeting convened to identify practice gaps in STI management and offers guidance beyond the CDC’s STD treatment guidelines. This presentation highlights the case of Carly, a 28-year-old woman, G3 P1102, who is 30 weeks pregnant. She presents at her routine prenatal visit reporting malodorous discharge and mild vaginal irritation. Review this case to get the latest expert guidance on best practices in trichomoniasis screening and treatment.
For more evidence-based, peer reviewed slides on reproductive health topics, visit www.arhp.org/CORE. Review a free, on-demand webinar on managing prevalent & problematic STIs and earn CME at www.arhp.org/STIwebinar.
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Conte...hivlifeinfo
Современное лечение ВИЧ: лечение ВИЧ у пациентов с вирусными гепатитами.Contemporary Management of HIV. Managing HIV in Viral Hepatitis Coinfection.2016
In this downloadable slideset, David L. Wyles, MD, and Program Director Eric S. Daar, MD, review key data and optimal approaches for ART management in patients with HIV and viral hepatitis coinfection.
Format: Microsoft PowerPoint (.ppt)
File size: 1.85 MB
Hepatitis C elimination in HIV-infected men who have sex with men: reality and challenges
Edward Cachay MD, MAS
February 23rd, 2018
UCSD HIV & Global Health Rounds
Современное лечение ВИЧ: новые парадигмы в АРТ / Contemporary Management of H...hivlifeinfo
Набор слайдов c рассмотрением важных вопросов об АРТ первого ряда, арв-препаратами пролонгированного действия и схемами АРТ с двумя препаратами, акцент в публикации на роль новых стратегий.
Amutha Rajagopal, MD
Associate Physician Diplomate
Division of Infectious Diseases & Global Public Health
Department of Medicine
University of California, San Diego
Epidemiological Profile and Clinical Spectrum of Hepatitis B-Ten Years Experi...JohnJulie1
Hepatitis B virus (HBV) infection, a pan global health problem, has already effected one-third of the world popula- tion. India harbours around 40 million HBV carriers, thus account- ing for 10–15% share of total pool of HBV carriers of the world. Every year over 100,000 Indians die due to illnesses related to HBV infection
ARV Therapy and the Role of Early Intervention presented by Dr. Rachel Baden, Harvard Medical Faculty Physician at the Fenway Health Center community education conference: An End To AIDS - How A State Bill Can Change Everything hosted by SearchForACure.org, the Fenway Health Center, and the MA Dept. of Public Health
Global Medical Cures™ | HIV TESTING IN USA
DISCLAIMER-
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
2014 Report: Medicines in Development for HIV/AIDSPhRMA
Biopharmaceutical Company Researchers Are Developing More Than 40 Medicines and Vaccines For HIV Infection Treatment and Prevention
Globally, approximately 35 million people are infected with human immunodeficiency virus (HIV), the virus that causes
acquired immune deficiency syndrome (AIDS). However, new infections have dropped by 38 percent since 2001, according to UNAIDS, the Joint United Nations Programme on HIV/AIDS.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Countdown: Confronting the HIV/HCV Coinfection Crisis
1. Countdown:Confronting the HIV/HCV CoinfectionCrisis Daniel Raymond Policy Director Harm Reduction Coalition (212) 213-6376 x29 raymond@harmreduction.org www.harmreduction.org
2. Coinfection by the numbers At least one in four PWHIV are coinfected with hepatitis C People coinfected with HIV have three times the risk of cirrhosis, liver failure, and death compared to people with HCV alone Cirrhosis will develop in one half of coinfected people within 30 years of HCV infection
4. 2011 in HCV = 1996 in HIV? The new cocktail: pegylated interferon + ribavirin + an HCV protease inhibitor Cures up to 79% in 24-48 weeks (vs. 46% for PEG IFN/RBV) Victrelis (boceprevir, Merck) approved by FDA on May 13, already in pharmacies Incivek (telaprevir, Vertex) approval announced this morning
5. Déjà vu: challenges with first-generation protease inhibitors Victrelis: taken 3 times daily with food; 12 pills/day total Viral resistance to HCV protease inhibitors is a major concern Multiple potential drug-drug interactions Added toxicities (anemia, rash, etc.) High cost: Victrelis price is $1,100/week on top of PEG IFN/RBV costs, Incivek is $49,200 for 12 weeks
6. HCV PIs and HIV coinfection Preliminary data on Incivek (telaprevir) in HIV/HCV coinfection: 68% undetectable at 12 weeks of treatment (out of 48 weeks total), vs. 14% with PEG IFN/RBV Incivek pilot coinfection study allowed a) HIV treatment naïve or b) on treatment with Truvada + ReyatazorSustiva Large phase III Incivek HIV/HCV study to launch later this year Victreliscoinfection pilot study underway; no data yet reported
7. Key points for HIV/HCV coinfection, 2011-2013 HIV doctors and patients have been waiting for better HCV treatment options for nearly a decade Many doctors will start using HCV protease inhibitors for their coinfected patients “off label” HCV treatment may require change in HAART regimen for some patients Landscape for next two years: triple therapy with Incivek or Victrelis
8. Coinfection challenges for Health Departments Falling through the cracks: no coinfection focus in National HIV/AIDS Strategy nor in the new HHS Viral Hepatitis Action Plan More pressure on ADAPs: formulary issues and likely increases in utilization Making coinfection care & treatment work for the most marginalized PWHIV Integrating HIV & HCV care with mental health, substance use treatment
10. Window period Après 2012, le déluge: Dozens of new HCV drugs in development 2nd generation protease inhibitors, polymerase inhibitors (nukes & non-nucleosides), NS5A inhibitors, & more Combination therapies: direct-acting antivirals w/out PEG INF +/- RBV Proof of concept: 4/11 cured with 24 weeks of BMS PI & NS5A inhibitor
11.
12. Meanwhile, in prevention… New generation of heroin users: harbinger of next HCV epidemic? (Massachusetts, Ohio) Clusters of acute HCV in HIV+ MSM: need an aggressive STI-style “screen and treat” approach Rapid HCV test: venous & fingerstick whole blood, filed for CLIA waiver, oral test expected 2011: antibody test only, can’t establish chronic infection without follow-up viral load test
13. Getting it right: Six action steps Map the coinfection crisis: who are they, where are they, how are they getting HIV care & support? Learning & teaching process: monitor Incivek & Victrelis uptake & utilization Strengthen internal health department champions’ voice & role Develop coinfection teams & task forces Litmus test: how will this serve our coinfected patients? Demand federal leadership & support: we need an HHS-level HIV/HCV summit
14.
15. Additional resources HRSA Hepatitis C & HIV Coinfection Care and Treatment Guide (2007) http://hab.hrsa.gov/deliverhivaidscare/files/coinfect.pdf HRSA Hepatitis C Treatment Expansion Initiative http://www.hrsa.gov/about/news/pressreleases/2010/101119hepatitisc.html NASTAD 2011 National ADAP Monitoring Project Annual Report (see Module 2 Supplement for viral hepatitis data) http://www.nastad.org/Programs/ADAP/ VA Hepatitis C Publications and Products http://www.hepatitis.va.gov/products/index.asp
16. Additional resources HIV i-Base Guide to Hepatitis C for People Living with HIV http://i-base.info/guides/hepc Treatment Action Group 2011 HCV Pipeline Report http://www.treatmentactiongroup.org/publication.aspx?id=4416